论文部分内容阅读
目的探讨Chk1、Chk2蛋白在胶质瘤和正常对照组织中的分布特点,以评价Chk1、Chk2作为胶质瘤治疗靶点的可行性。方法应用免疫组织化学SABC法检测Chk1、Chk2蛋白在80例胶质瘤和18例正常脑组织中的表达,并结合病理特点进行分析。结果 Chk1、Chk2蛋白在各类型胶质瘤和正常脑组织中均表达,Chk1蛋白在胶质瘤中的阳性表达水平明显高于正常脑组织(P=0.027);Chk2蛋白在胶质瘤和正常脑组织中的阳性表达水平无显著性差异(P=0.173)。Chk1、Chk2蛋白表达水平在高级别胶质瘤(WHOⅢ～Ⅳ级)和低级别胶质瘤(WHOⅠ～Ⅱ级)中无明显差异(P=0.301、0.135)。Chk1和Chk2蛋白在胶质瘤中的表达呈正相关(r=0.795,P<0.001)。结论 Chk1在胶质瘤中高表达,是胶质瘤的特异性表达分子,可以作为胶质瘤治疗的靶点,Chk2与Chk1在胶质瘤中的表达呈正相关,联合灭活Chk1、Chk2来增强胶质瘤治疗敏感性非常重要。
Objective To investigate the distribution of Chk1 and Chk2 proteins in gliomas and normal controls to evaluate the feasibility of Chk1 and Chk2 as targets for glioma therapy. Methods Immunohistochemical SABC method was used to detect the expression of Chk1 and Chk2 proteins in 80 gliomas and 18 normal brain tissues, and their pathological features were analyzed. Results Chk1 and Chk2 proteins were expressed in all types of gliomas and normal brain tissues. The positive expression of Chk1 protein in gliomas was significantly higher than that in normal brain tissues (P = 0.027). The expression of Chk2 protein in gliomas and normal There was no significant difference in the positive expression of brain tissue (P = 0.173). Chk1 and Chk2 protein expression levels in high grade gliomas (WHO Ⅲ ~ Ⅳ grade) and low grade glioma (WHO Ⅰ ~ Ⅱ grade) no significant difference (P = 0.301,0.135). Chk1 and Chk2 protein expression in gliomas were positively correlated (r = 0.795, P <0.001). Conclusion Chk1 is highly expressed in glioma and is a specific expression of glioma, which can be used as a target for the treatment of glioma. Chk2 is positively correlated with the expression of Chk1 in gliomas, and combined with the inactivation of Chk1 and Chk2 The sensitivity of glioma treatment is very important.